BioCentury | Jul 29, 2020
Distillery Therapeutics

CAPN2 inhibition for concussion-associated neuropathy and behavioral changes

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the calcium-dependent protease CAPN2 could treat neuropathy and behavioral changes caused by repeated concussions. In a mouse model of traumatic brain injury mediated by controlled cortical impact, excitatory neuron-specific...
BioCentury | Dec 20, 2019

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy An adeno-associated viral vector deliverying CAPN3, a calcium-dependent protease expressed at low levels in the heart and primarily expressed in skeletal muscle, could treat limb-girdle muscular dystrophy type 2A...
BioCentury | Sep 27, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

...the company; the pharma has since declined the option. BLD-2660, which inhibits CAPN1, CAPN2 and CAPN9...
...lack of CAPN9 prevented a TGFβ-induced pathway that contributes to fibrosis development. Mice without functional CAPN9...
...on future financing plans. Targets: CAPN1 - Calpain 1; CAPN2 - Calpain 2; CAPN9 - Calpain 9...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting CAPN9 to treat fibrosis

...DISEASE CATEGORY: Pulmonary; hepatic; cardiovascular INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis Inhibition of CAPN9 could...
...treat fibrosis by blocking a TGFβ-induced pathway that contributes to fibrosis development. Two tool compound CAPN9...
...into myofibroblasts -- a process linked to fibrosis development. Mice with a loss-of-function mutation in CAPN9...
BioCentury | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

...Johns Hopkins University reported in a Science Translational Medicine paper that inhibition or lack of CAPN9...
...suggesting the cysteine protease as a new target to treat the disease. Mice without functional CAPN9...
...ADAR (ADAR1) - Adenosine deaminase RNA-specific; DYRK1A - Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A; CAPN9 - Calpain 9...
BioCentury | Feb 3, 2017
Financial News

Capnia financial update

On Jan. 27, inflammation, neurology and diagnostic company Capnia Inc. (NASDAQ:CAPN) entered into a 30-month stock purchase agreement with Aspire Capital Fund for up to $17 million. Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Alicia Parker...
BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Calpain 6 (CAPN6)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAPN6 could help treat atherosclerosis. In patients, CAPN6 expression on macrophages in atheromas was associated with disease severity. In a mouse model of atherosclerosis,...
BioCentury | Jul 11, 2016
Financial News

Capnia completes private placement of convertible preferred stock

Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Business: Diagnostic Date completed: 2016-07-06 Type: Private placement of convertible preferred stock Raised: $3.2 million Shares: 3,151 Price: $1,000 Shares after offering: 15.9 million Placement agent: Maxim Group Investor:...
BioCentury | Feb 29, 2016
Clinical News

Nasal CO2: Phase II started

Capnia began a single-blind, U.S. Phase II trial to evaluate nasal CO2 in about 50 patients. Patients will receive 6 doses of nasal CO2 or placebo, with each dose given over 10 seconds, in the...
BioCentury | Jan 18, 2016
Financial News

Capnia completes private placement of convertible preferred stock and warrants

Capnia Inc. (NASDAQ:CAPN), Redwood City, Calif. Business: Diagnostic Date completed: 2016-01-11 Type: Private placement of convertible preferred stock and warrants Raised: $5.4 million Shares: 5,445 Price: $1,000 Shares outstanding prior: 12.4 million Placement agent: Maxim...
Items per page:
1 - 10 of 57